Abstract Summary Pharmacological enhancement of endoplasmic reticulum (ER) proteostasis is an attractive strategy to mitigate pathology linked to etiologically-diverse protein misfolding diseases.

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial.

Praziquantel (PZQ) is widely used to treat schistosomiasis. However, this chiral active pharmaceutical ingredient (API) is still produced as a racemic compound while only the (R)-enantiomer is active.